Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF
Open Access
- 1 November 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (11) , 2490-2496
- https://doi.org/10.1093/humrep/deh471
Abstract
BACKGROUND: The significance of suppressed LH levels in GnRH antagonist cycles for IVF outcome is currently unknown. The purpose of this study was to evaluate prospectively the association between LH levels and ongoing pregnancy achievement after GnRH antagonist initiation in IVF cycles. METHODS: Ovarian stimulation with a fixed dose of 200 IU recombinant FSH and daily GnRH antagonist (ganirelix) 0.25 mg from day 6 of stimulation was initiated in 116 women. Patients were not pretreated with an oral contraceptive. Induction of final oocyte maturation was performed with HCG 10 000 IU as soon as three follicles of ≥17 mm were present in ultrasound, and was followed by oocyte pick-up, conventional IVF or ICSI, and embryo transfer. The luteal phase was supplemented with vaginal progesterone. RESULTS: A significant decrease of both ongoing pregnancy rate and implantation rate was present across groups of patients with increasing LH levels. The highest implantation rate and ongoing pregnancy rate was present in those patients with LH levels on day 8 of stimulation ≤0.5 IU/l. CONCLUSIONS: Profound suppression of LH on day 8 of stimulation is associated with a significantly higher chance of achieving an ongoing pregnancy. More studies are necessary to evaluate this phenomenon further.Keywords
This publication has 23 references indexed in Scilit:
- Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonistsFertility and Sterility, 2004
- The merits of blastocyst versus cleavage stage embryo transfer: a Cochrane reviewHuman Reproduction, 2004
- Recombinant follicle stimulating hormone (R-FSH) versus recombinant luteinizing hormone (R-LH) and R-FSH treatment in combination with cetrorelix after oral contraceptive programming in IVF/ICSI; a feasibility studyFertility and Sterility, 2002
- Is exogenous LH necessary when using GnRH antagonist in IVF ovarian hyperstimulation?Fertility and Sterility, 2002
- Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulationHuman Reproduction, 2002
- Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteersFertility and Sterility, 1999
- Luteinizing Hormone Increases Estradiol Secretion but has no Effect on Progesterone Concentrations in the Late Follicular Phase of In Vitro Fertilization Cycles in Women Treated with Gonadotropin-Releasing Hormone Agonist and Follicle-Stimulating HormoneFertility and Sterility, 1998
- Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcomeFertility and Sterility, 1997
- Experience Using Preparations of Follicle-Stimulating Hormone Alone to Stimulate the Ovaries for Assisted Conception after Pituitary Desensitisation and Simplified Management of TreatmentHormone Research, 1995
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985